Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00749203 · ClinicalTrials.gov registry record · Phase 2
Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)
A Phase 2 study of Depression and PTSD, sponsored by Dennis Charney.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT00749203 is a Phase 2 study of Depression and PTSD that has completed, run by Dennis Charney. The registered enrollment target is 41 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00749203, a Phase 2 study of Depression and PTSD, has completed, sponsored by Dennis Charney.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the proposed study is to test if a single IV dose of ketamine (0.5 mg/kg) decreases symptoms of PTSD.
Conditions Studied
Interventions
- DRUG Ketamine
- DRUG Midazolam
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2009-01 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00749203
The ClinicalTrials.gov registry entry for NCT00749203 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (95% lower). The listed sponsor is Dennis Charney, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT00749203 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00749203 about?
NCT00749203 is a clinical study titled "Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)". The objective of the proposed study is to test if a single IV dose of ketamine (0.5 mg/kg) decreases symptoms of PTSD.
What is the current status of trial NCT00749203?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2009-01. Estimated completion is 2013-09.
What conditions does trial NCT00749203 study?
This clinical trial studies the following conditions: Depression, PTSD, Stress Disorders, Post-Traumatic, Anxiety Disorder.
What interventions are being tested in trial NCT00749203?
The interventions under investigation include: Ketamine (DRUG), Midazolam (DRUG).
Who is sponsoring clinical trial NCT00749203?
This trial is sponsored by Dennis Charney, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00749203 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.